LakePharma and NJ Bio partner on ‘one-stop’ ADC manufacturing service

By Vassia Barba

- Last updated on GMT

(Image: Getty/extender01)
(Image: Getty/extender01)

Related tags Antibody drug conjugates antibody-drug conjugates Antibody Contract manufacturing

Antibody-focused service providers merge their offerings to create a ‘seamless workflow’ on antibody-drug conjugates to help save developers’ time and costs.

LakePharma, a US-based biologics contract research, development, and manufacturing organization (CRDMO), will work jointly with NJ Biopharmaceuticals, a provider of chemistry and biology services, to create a streamlined antibody-drug conjugate (ADC) development service.

Specifically, the agreement will see LakePharma manufacture and provide antibodies as starting materials for ADC development, which will be carried out by NJ Bio, in order to support drug developers working on such treatments.

This joint service, leveraging the capabilities of both companies in their field, is expected to create a ‘seamless workflow’ for clients, from initial antibody discovery to the production of the drug conjugates in a manner “significantly more efficient both in time and expense,”​ LakePharma stated.

Commenting on the partnership, Nareshkumar Jain, CEO of NJ Bio, stated that the partnership will expand and add value to the ADC services that the companies currently provide, creating cost-effective solutions through the provision of complementary service offerings.

The therapeutic potential of ADCs and their uptake from the industry has seen several companies establishing partnerships, such as AstraZeneca with Daiichi Sankyo​ last year, as well as investment in capabilities, such as that of Lonza​ – which stated that it was preparing for a ‘new wave’ of ADC therapies.

Related news

Show more

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers